α-synuclein genetic variability: A biomarker for dementia in Parkinson disease

Annals of Neurology

Volumn 79, Issue 6, 2016, Pages 991-999

  Guella, Ilaria ^a   Evans, Daniel M ^a   Szu Tu, Chelsea ^a   Nosova, Ekaterina ^a   Bortnick, Stephanie F ^a   Goldman, Jennifer G ^b   Dalrymple Alford, John C ^c   Geurtsen, Gert J ^d   Litvan, Irene ^e   Ross, Owen A ^f   Middleton, Lefkos T ^g   Parkkinen, Laura ^h   Farrer, Matthew J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c NEW ZEALAND BRAIN RESEARCH INSTITUTE   (New Zealand)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MAYO GRADUATE SCHOOL   (United States)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HIGH THROUGHPUT SEQUENCING; HUMAN; INTRON; MAJOR CLINICAL STUDY; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; CASE CONTROL STUDY; CLINICAL TRIAL; COGNITIVE DEFECT; COMPLICATION; DEMENTIA; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; MULTICENTER STUDY; PSYCHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; BIOMARKERS; CASE-CONTROL STUDIES; COGNITIVE DYSFUNCTION; DEMENTIA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LEWY BODY DISEASE; MALE; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84965123533     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24664     Document Type: Article

References (51)

1. Muslimovic D, Post B, Speelman JD, Schmand B,. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005; 65: 1239-1245.
2. Litvan I, Aarsland D, Adler CH, et al., MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord 2011; 26: 1814-1824.
3. Aarsland D, Andersen K, Larsen JP, et al., Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387-392.
4. Hely MA, Reid WG, Adena MA, et al., The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-844.
5. Rosenthal E, Brennan L, Xie S, et al., Association between cognition and function in patients with Parkinson disease with and without dementia. Mov Disord 2010; 25: 1170-1176.
6. Emre M, Aarsland D, Brown R, et al., Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689-1707; quiz 837.
7. Lippa CF, Duda JE, Grossman M, et al., DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007; 68: 812-819.
8. McKeith IG,. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 2006; 9 (3 suppl): 417-423.
9. Ballard C, Ziabreva I, Perry R, et al., Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006; 67: 1931-1934.
10. Guo L, Itaya M, Takanashi M, et al., Relationship between Parkinson disease with dementia and dementia with Lewy bodies. Parkinsonism Relat Disord 2005; 11: 305-309.
11. Harding AJ, Halliday GM,. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 2001; 102: 355-363.
12. Jellinger KA,. Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study. J Neural Transm Suppl 2007;(72): 91-104.
13. Howlett DR, Whitfield D, Johnson M, et al., Regional multiple pathology scores are associated with cognitive decline in Lewy body dementias. Brain Pathol 2015; 25: 401-408.
14. Ruffmann C, Calboli FC, Bravi I, et al., Cortical Lewy bodies and Aβ burden are associated with prevalence and timing of dementia in Lewy body diseases. Neuropathol Appl Neurobiol 2015; DOI: 10.1111/nan.12294.
15. Poulopoulos M, Levy OA, Alcalay RN,. The neuropathology of genetic Parkinson's disease. Mov Disord 2012; 27: 831-842.
16. Rajput AH, Rozdilsky B, Rajput A,. Accuracy of clinical diagnosis in parkinsonism-a prospective study. Can J Neurol Sci 1991; 18: 275-278.
17. Gelb DJ, Oliver E, Gilman S,. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33-39.
18. Hughes AJ, Daniel SE, Kilford L, Lees AJ,. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
19. McKeith IG, Dickson DW, Lowe J, et al., Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872.
20. Dalrymple-Alford JC, MacAskill MR, Nakas CT, et al., The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010; 75: 1717-1725.
21. Hu MT, Szewczyk-Krolikowski K, Tomlinson P, et al., Predictors of cognitive impairment in an early stage Parkinson's disease cohort. Mov Disord 2014; 29: 351-359.
22. Johnson J, Hague SM, Hanson M, et al., SNCA multiplication is not a common cause of Parkinson disease or dementia with Lewy bodies. Neurology 2004; 63: 554-556.
23. Steele JC, Guella I, Szu-Tu C, et al., Defining neurodegeneration on Guam by targeted genomic sequencing. Ann Neurol 2015; 77: 458-468.
24. Wang K, Li M, Hakonarson H,. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010; 38: e164.
25. Barrett JC, Fry B, Maller J, Daly MJ,. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
26. Li H, Handsaker B, Wysoker A, et al., The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009; 25: 2078-2079.
27. Purcell S, Neale B, Todd-Brown K, et al., PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
28. Nalls MA, Pankratz N, Lill CM, et al., Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 2014; 46: 989-993.
29. Satake W, Nakabayashi Y, Mizuta I, et al., Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009; 41: 1303-1307.
30. Maraganore DM, de Andrade M, Elbaz A, et al., Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006; 296: 661-670.
31. Mata IF, Shi M, Agarwal P, et al., SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol 2010; 67: 1350-1356.
32. Winkler S, Hagenah J, Lincoln S, et al., alpha-Synuclein and Parkinson disease susceptibility. Neurology 2007; 69: 1745-1750.
33. Bras J, Guerreiro R, Darwent L, et al., Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet 2014; 23: 6139-6146.
34. Nishioka K, Wider C, Vilarino-Guell C, et al., Association of alpha-, beta-, and gamma-synuclein with diffuse Lewy body disease. Arch Neurol 2010; 67: 970-975.
35. Heintzman ND, Hon GC, Hawkins RD, et al., Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 2009; 459: 108-112.
36. Gymrek M, Willems T, Guilmatre A, et al., Abundant contribution of short tandem repeats to gene expression variation in humans. Nat Genet 2016; 48: 22-29.
37. Beyer K, Ispierto L, Latorre P, et al., Alpha- and beta-synuclein expression in Parkinson disease with and without dementia. J Neurol Sci 2011; 310: 112-117.
38. Chiba-Falek O, Lopez GJ, Nussbaum RL,. Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. Mov Disord 2006; 21: 1703-1708.
39. Kingsbury AE, Daniel SE, Sangha H, et al., Alteration in alpha-synuclein mRNA expression in Parkinson's disease. Mov Disord 2004; 19: 162-170.
40. Neystat M, Lynch T, Przedborski S, et al., Alpha-synuclein expression in substantia nigra and cortex in Parkinson's disease. Mov Disord 1999; 14: 417-422.
41. Fuchs J, Tichopad A, Golub Y, et al., Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J 2008; 22: 1327-1334.
42. Linnertz C, Saucier L, Ge D, et al., Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues. PLoS One 2009; 4: e7480.
43. Sotiriou S, Gibney G, Baxevanis AD, Nussbaum RL,. A single nucleotide polymorphism in the 3'UTR of the SNCA gene encoding alpha-synuclein is a new potential susceptibility locus for Parkinson disease. Neurosci Lett 2009; 461: 196-201.
44. Sterling L, Walter M, Ting D, Schule B,. Discovery of functional non-coding conserved regions in the alpha-synuclein gene locus. F1000Res 2014; 3: 259.
45. Lutz MW, Saul R, Linnertz C, et al., A cytosine-thymine (CT)-rich haplotype in intron 4 of SNCA confers risk for Lewy body pathology in Alzheimer's disease and affects SNCA expression. Alzheimers Dement 2015; 11: 1133-1143.
46. Kempster PA, O'Sullivan SS, Holton JL, et al., Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain 2010; 133: 1755-1762.
47. Williams-Gray CH, Evans JR, Goris A, et al., The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009; 132 (pt 11): 2958-2969.
48. Levy G, Tang MX, Cote LJ, et al., Motor impairment in PD: relationship to incident dementia and age. Neurology 2000; 55: 539-544.
49. Chen-Plotkin AS,. Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron 2014; 84: 594-607.
50. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011; 95: 629-635.
51. Geurtsen GJ, Hoogland J, Goldman JG, et al., Parkinson's disease mild cognitive impairment: application and validation of the criteria. J Parkinsons Dis 2014; 4: 131-137.